<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961803</url>
  </required_header>
  <id_info>
    <org_study_id>MD1003CT2014-01AMN</org_study_id>
    <nct_id>NCT02961803</nct_id>
  </id_info>
  <brief_title>MD1003-AMN MD1003 in Adrenomyeloneuropathy</brief_title>
  <official_title>MD1003 in Adrenomyeloneuropathy : a Randomized Double Blind Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedDay Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedDay Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to demonstrate the superiority of biotin at 300 mg/day
      over placebo in the clinical improvement (walking tests) of patients with
      adrenomyeloneuropathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AMN and progressive multiple sclerosis share some similarities including progressive spastic
      paraparesis and secondary energy failure leading to progressive axonal degeneration.
      Therefore, it was hypothesized that high doses of biotin might be efficient in patients with
      AMN.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of 2 minutes walking test (2MWT) between Months 12 and baseline</measure>
    <time_frame>Baseline and 12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improved 2-Minutes-Walk-Tests (2MWT) of at least 20%</measure>
    <time_frame>Baseline, 9 months, 12 months</time_frame>
    <description>at Months 9 and Months 12 compared to the best value among screening and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improved TW25 (time to walk 25 feet) of at least 20%</measure>
    <time_frame>Baseline, 9 months, 12 months</time_frame>
    <description>at Months 9 and Months 12 compared to the best value among screening and baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in TW25 (time to walk 25 feet)</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed up and Go test (TUG)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euroqol EQ-5D questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of Life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualiveen Questionnaire</measure>
    <time_frame>12 Months</time_frame>
    <description>Qualiveen to evaluate urinary function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Adrenomyeloneuropathy</condition>
  <condition>Adrenoleukodystrophy</condition>
  <condition>AMN</condition>
  <arm_group>
    <arm_group_label>MD1003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MD1003 100mg capsules, 1 capsule tid for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MD1003 100 mg capsule</intervention_name>
    <arm_group_label>MD1003</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>High Dose Biotin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ABCD1 gene mutation identified

          -  Elevated plasma VLCFA

          -  Clinical signs of AMN with at least pyramidal signs in the lower limbs and
             difficulties to walk

          -  EDSS score ≥ 3.5 and ≤ 6.5

          -  Normal brain MRI or brain MRI showing :

          -  abnormalities that can be observed in AMN patients without cerebral demyelination with
             a maximum Loes score of 4

          -  and/or stable (≥6 months) cerebral demyelination without gadolinium enhancement with a
             Loes score ≤12.

          -  Appropriate steroid replacement if adrenal insufficiency is present

          -  Likely to be able to participate in all scheduled evaluation visits and complete all
             required study procedures

          -  Signed and dated written informed consent to participate in the study in accordance
             with local regulations

          -  Affiliated to a Health Insurance

        Exclusion Criteria:

          -  Brain MRI abnormalities with a Loes score &gt; 12 or with gadolinium enhancement

          -  Any progressive neurological disease other than AMN

          -  Impossibility to perform the walk tests and the TUG test

          -  Patients with uncontrolled hepatic disorder, renal or cardiovascular disease, or any
             progressive malignancy

          -  Any new medication for AMN including Fampridine initiated less than 1 month prior to
             inclusion

          -  Contra-indications for MRI procedure such as subjects with paramagnetic materials in
             the body, such as aneurysm clips, pacemakers, intraocular metal or cochlear implants.

          -  Inclusion in another therapeutic clinical trial for ALD

          -  Not easily contactable by the investigator in case of emergency or not capable to call
             the investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Aubourg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Le Kremlin-Bicêtre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederic Sedel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medday Pharmeuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS-Ambulanz Fachkrankenhaus Hubertusburg</name>
      <address>
        <city>Wermsdorf</city>
        <zip>04779</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals / Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.medday-pharma.com</url>
    <description>Sponsor</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMN</keyword>
  <keyword>MD1003</keyword>
  <keyword>Adrenomyeloneuropathy</keyword>
  <keyword>ALD</keyword>
  <keyword>Adrenoleukodystrophy</keyword>
  <keyword>Biotin</keyword>
  <keyword>2MWT</keyword>
  <keyword>Two-minute walk test</keyword>
  <keyword>TW25</keyword>
  <keyword>Timed 25-Foot Walk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biotin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

